1481 related articles for article (PubMed ID: 8747596)
1. Immunohistochemical detection of p53 in melanomas with rare p53 gene mutations is associated with mdm-2 overexpression.
Poremba C; Yandell DW; Metze D; Kamanabrou D; Böcker W; Dockhorn-Dworniczak B
Oncol Res; 1995; 7(7-8):331-9. PubMed ID: 8747596
[TBL] [Abstract][Full Text] [Related]
2. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions.
Ruggeri BA; Huang L; Berger D; Chang H; Klein-Szanto AJ; Goodrow T; Wood M; Obara T; Heath CW; Lynch H
Cancer; 1997 Feb; 79(4):700-16. PubMed ID: 9024708
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical and molecular evaluation of the mdm-2 gene product in bronchogenic carcinoma.
Gorgoulis VG; Rassidakis GZ; Karameris AM; Papastamatiou H; Trigidou R; Veslemes M; Rassidakis AN; Kittas C
Mod Pathol; 1996 May; 9(5):544-54. PubMed ID: 8733770
[TBL] [Abstract][Full Text] [Related]
4. mdm-2 expression correlates with wild-type p53 status in esophageal adenocarcinoma.
Soslow RA; Altorki NK; Yang G; Xie D; Yang CS
Mod Pathol; 1999 Jun; 12(6):580-6. PubMed ID: 10392633
[TBL] [Abstract][Full Text] [Related]
5. Analysis of the p53 and MDM-2 gene in acute myeloid leukemia.
Seliger B; Papadileris S; Vogel D; Hess G; Brendel C; Störkel S; Ortel J; Kolbe K; Huber C; Huhn D; Neubauer A
Eur J Haematol; 1996 Sep; 57(3):230-40. PubMed ID: 8898928
[TBL] [Abstract][Full Text] [Related]
6. P53 expression in Reed-Sternberg cells does not correlate with gene mutations in Hodgkin's disease.
Elenitoba-Johnson KS; Medeiros LJ; Khorsand J; King TC
Am J Clin Pathol; 1996 Dec; 106(6):728-38. PubMed ID: 8980348
[TBL] [Abstract][Full Text] [Related]
7. Relative quantitation of p53 and MDM2 gene expression in leiomyosarcoma; real-time semi-quantitative reverse transcription-polymerase chain reaction.
Miyajima K; Tamiya S; Oda Y; Adachi T; Konomoto T; Toyoshiba H; Masuda K; Tsuneyoshi M
Cancer Lett; 2001 Mar; 164(2):177-88. PubMed ID: 11179833
[TBL] [Abstract][Full Text] [Related]
8. p53 and mdm-2 expression in malignant melanoma: an immunocytochemical study of expression of p53, mdm-2, and markers of cell proliferation in primary versus metastatic tumors.
Gelsleichter L; Gown AM; Zarbo RJ; Wang E; Coltrera MD
Mod Pathol; 1995 Jun; 8(5):530-5. PubMed ID: 7675773
[TBL] [Abstract][Full Text] [Related]
9. Expression and mutation of the tumor suppressor gene p53 in AIDS-associated Kaposi's sarcoma.
Li JJ; Huang YQ; Cockerell CJ; Zhang WG; Nicolaides A; Friedman-Kien AE
Am J Dermatopathol; 1997 Aug; 19(4):373-8. PubMed ID: 9261472
[TBL] [Abstract][Full Text] [Related]
10. p53 gene mutation and expression in naevi and melanomas.
Sparrow LE; Soong R; Dawkins HJ; Iacopetta BJ; Heenan PJ
Melanoma Res; 1995 Apr; 5(2):93-100. PubMed ID: 7620345
[TBL] [Abstract][Full Text] [Related]
11. Absence of p53 gene mutations in cutaneous melanoma.
Lübbe J; Reichel M; Burg G; Kleihues P
J Invest Dermatol; 1994 May; 102(5):819-21. PubMed ID: 8176269
[TBL] [Abstract][Full Text] [Related]
12. p53 mutation without allelic loss and absence of mdm-2 amplification in a transplantable hamster pancreatic ductal adenocarcinoma and derived cell lines but not primary ductal adenocarcinomas in hamsters.
Okita S; Tsutsumi M; Onji M; Konishi Y
Mol Carcinog; 1995 Aug; 13(4):266-71. PubMed ID: 7646765
[TBL] [Abstract][Full Text] [Related]
13. The p53 and mdm-2 genes in human testicular germ-cell tumors.
Riou G; Barrois M; Prost S; Terrier MJ; Theodore C; Levine AJ
Mol Carcinog; 1995 Mar; 12(3):124-31. PubMed ID: 7893365
[TBL] [Abstract][Full Text] [Related]
14. p53 mutations and MDM-2 amplification in renal cell cancers.
Imai Y; Strohmeyer TG; Fleischhacker M; Slamon DJ; Koeffler HP
Mod Pathol; 1994 Sep; 7(7):766-70. PubMed ID: 7824511
[TBL] [Abstract][Full Text] [Related]
15. Analysis of the K-ras and p53 pathways in X-ray-induced lung tumors in the rat.
Belinsky SA; Middleton SK; Picksley SM; Hahn FF; Nikula KJ
Radiat Res; 1996 Apr; 145(4):449-56. PubMed ID: 8600505
[TBL] [Abstract][Full Text] [Related]
16. p53 mutations in human cutaneous melanoma correlate with sun exposure but are not always involved in melanomagenesis.
Zerp SF; van Elsas A; Peltenburg LT; Schrier PI
Br J Cancer; 1999 Feb; 79(5-6):921-6. PubMed ID: 10070891
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemically detectable p53 and mdm-2 oncoprotein expression in astrocytic gliomas and their correlation to cell proliferation.
Dietzmann K; von Bossanyi P; Sallaba J; Kirches E; Synowitz HJ; Warich-Kirches M
Gen Diagn Pathol; 1996 May; 141(5-6):339-44. PubMed ID: 8780933
[TBL] [Abstract][Full Text] [Related]
18. MDM2 overexpression does not account for stabilization of wild-type p53 protein in non-Hodgkin's lymphomas.
Maestro R; Gloghini A; Doglioni C; Gasparotto D; Vukosavljevic T; De Re V; Laurino L; Carbone A; Boiocchi M
Blood; 1995 Jun; 85(11):3239-46. PubMed ID: 7756655
[TBL] [Abstract][Full Text] [Related]
19. Overexpression and mutations of p53 in metastatic malignant melanomas.
Hartmann A; Blaszyk H; Cunningham JS; McGovern RM; Schroeder JS; Helander SD; Pittelkow MR; Sommer SS; Kovach JS
Int J Cancer; 1996 Jul; 67(3):313-7. PubMed ID: 8707401
[TBL] [Abstract][Full Text] [Related]
20. [Role of functional inactivation of p53 from MDM2 overexpression in hepatocarcinogenesis].
Luo YL; Cheng RX; Feng DY
Hunan Yi Ke Da Xue Xue Bao; 2001 Feb; 26(1):13-6. PubMed ID: 12536604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]